

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Otterbein et al. Art Unit : 1651
Serial No. : 10/600,182 Examiner : Sandra E. Saucier
Filed : June 20, 2003 Conf. No. : 8996
Title : PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND
PRODUCTS OF HEME DEGRADATION

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Applicants request consideration of the reference listed on the attached PTO-1449 form.
A copy of the reference is enclosed.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. The reference was published online August 22, 2007, and was therefore not known to any individual designated in CFR § 1.56(c) more than three months prior to the filing of this statement. Further, the reference was not cited in a communication from a foreign patent office in a counterpart application.

No fee is believed due. Please apply any charges or credits to Deposit Account
No. 06-1050, referencing Attorney Docket No. 13681-012001.

Respectfully submitted,

Date: 10/2/07



Todd E. Garcia, Ph.D.
Reg. No. 54,112

Fish & Richardson P.C.
Telephone: (617) 542-5070
Facsimile: (617) 542-8906